Registry of pre-mixed solutions for critically ill patients on renal therapy
Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy (PrioR): a Multicenter, Prospective Real-world
This study is collecting information from critically ill patients on kidney treatment using pre-mixed solutions to see how well these solutions work in real-life situations.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 220 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Vantive Health LLC Industry-sponsored |
| Locations | 10 sites (Beijing and 9 other locations) |
| Trial ID | NCT06983509 on ClinicalTrials.gov |
What this trial studies
This multicenter, prospective registry collects demographic and clinical data from critically ill patients receiving continuous renal replacement therapy (CRRT) with pre-mixed solutions. The study aims to evaluate the clinical applicability of these solutions in real-world settings across approximately 10 sites in China. Data will be gathered from the initiation of CRRT with the pre-mixed solutions until their cessation, with a follow-up period extending to 30 days post-treatment.
Who should consider this trial
Good fit: Ideal candidates are critically ill patients aged 18 to 80 who require CRRT and consent to use one of the specified pre-mixed solutions.
Not a fit: Patients with chronic kidney failure on maintenance dialysis or those who cannot tolerate the pre-mixed solutions will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and effectiveness of pre-mixed solutions in critically ill patients undergoing renal therapy.
How similar studies have performed: While this approach is observational, similar studies have shown promise in evaluating treatment efficacy in critical care settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 ≤ age \< 80 years old. * Patients admitted to the intensive care unit (ICU) and in need of CRRT. * Patients are willing to receive CRRT with at least one of three pre-mixed solutions: Regiocit, Biphozyl, or Prismasol 2. Exclusion Criteria: * Patients with chronic kidney failure who are receiving maintenance dialysis. * Patients expected to require the premixed solution for less than 24 hours. * Patients who are allergic or have contraindications to components of pre-mixed solutions, as determined by the investigators. * Patients who have participated in other interventional studies within the last 30 days. * Patients who are pregnant, breastfeeding, or abortus imminence.
Where this trial is running
Beijing and 9 other locations
- Beijing Chao-yang Hospital, Capital Medical University — Beijing, China (Recruiting)
- Beijing Anzhen Hospital, Capital Medical University — Beijing, China (Recruiting)
- Xuanwu Hospital Capital Medical University — Beijing, China (Recruiting)
- The First Affiliated Hospital of Chongqing Medical University — Chongqing, China (Recruiting)
- The First People's Hospital of Guangzhou — Guangzhou, China (Recruiting)
- Zhujiang Hospital, Southern Medical University — Guangzhou, China (Recruiting)
- Zhejiang Provincial People's Hospital — Hangzhou, China (Recruiting)
- Shanghai East Hospital — Shangai, China (Recruiting)
- ZhongShan Hospital Fudan University — Shanghai, China (Recruiting)
- Zhongnan Hospital, Wuhan University — Wuhan, China (Recruiting)
Study contacts
- Study coordinator: Vantive Global CORP Clinical Trials Disclosure
- Email: Global.CORP.ClinicalTrialsDisclosure@vantive.com
- Phone: +1 2249484283
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.